Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer
Related Experiment Video
Updated: Aug 21, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
María del Refugio González-Losa1, Miguel A Laviada Mier y Teran, Marylín Puerto-Solís
1Virology Laboratory, Regional Research Center Dr Hideyo Noguchi, Autonomous University of Yucatán, Mérida, Yucatán, Mexico. glosa@tunku.uady.mx
Background:
Cervical cancer is the second most common cancer in women worldwide. Infection with human papillomavirus (HPV) 16 is an important risk factor associated with cervical cancer, more than 50% of cervical cancer tissues have DNA of HPV 16. Intratypic variants have been reported, although they differ in prevalence, biological and biochemical properties, their implication in the aetiology of cervical cancer is still uncertain.
Objective:
To identify HPV type 16 E6 variants among Mexican women with diagnosis of low-grade squamous intraepithelial lesion (LSIL) or invasive cancer (IC).
Study Design:
Forty HPV16-positive samples were included, 15 were from women with LSIL, 25 from women with IC; 610 pb from the E6 gene were amplified by PCR and the variant status subsequently determined by hybridization with 27 biotinilated probes. Statistical analysis was performed with chi2, odds ratio (OR).
Results:
In the LSIL group we only found ten (66%) EP and five (33%) EP350G variants. In the IC group, four variants were found; 11 (44%) AA, seven (28%) EP, six (24%) EP350G, one (4%) Af2. Comparison of the frequency of variants differed from EP in both groups of patients (P=0.01) with an odds ratio (OR) of 5.14 (CI 95% [1.07-26.56]).
Conclusion:
This study demonstrates an association between HPV type 16 variants different from prototype (EP) and invasive cervical cancer.
